t(10;10)(q25;q26) FGFR2::SHTN1

Genes involved

FGFR2 (10q26.13)

SHTN1 (10q25.3)

Oncogenic mechanisms

Constitutive activation of FGFR2 tyrosine kinase activity

Targeted therapy

Erdafitinib

infigratinib

pemigatinib

Tumor type

Cholangiocarcinoma

non–Small Cell Lung Cancer

Highly cited references

Pubmed IDYearTitleCitations
343636822021Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation.45
399363512025Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.0

Bibliography

Pubmed IDPublication YearTitleAuthors
296176622018Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.Gao Q, et al
302678392019Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.Qin A, et al